Company Licenses Caspase-1 From Johannes Gutenberg University, Mainz, Germany
SAN DIEGO, Aug. 22 /PRNewswire-FirstCall/ -- Biosite(R) Incorporated
(Nasdaq: BSTE) today announced it has signed an exclusive license with
Johannes Gutenberg University, Mainz, Germany for Caspase-1, a potentially
important cardiovascular disease biomarker.
Under the terms of the license agreement, Biosite is collaborating with
the University of Mainz to investigate possible clinical applications for the
biomarker. The financial terms of the agreement were not disclosed.
"Each year, cardiovascular diseases top the list of the country's most
serious health problems, and although Biosite has commercialized products on
the market addressing cardiovascular diseases, it is an important area of
ongoing investigation for our Biosite Discovery program," said Gunars Valkirs,
Ph.D., Biosite's senior vice president Biosite Discovery.
About Biosite Incorporated
Biosite Incorporated is a leading bio-medical company commercializing
proteomics discoveries for the advancement of medical diagnosis. The
Company's products contribute to improvements in medical care by aiding
physicians in the diagnosis of critical diseases and health conditions.
Biosite's Triage(R) rapid diagnostics are used in approximately 50 percent of
U.S. hospitals and in over 50 international markets. Information on Biosite
can be found at http://www.biosite.com.
Except for the historical information presented herein, matters discussed
in this press release are forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially from any
future results, performance or achievements expressed or implied by such
statements. Statements that are not historical facts, including but not
limited to statements that are preceded by, followed by, or that include the
words "will"; "believes"; "should"; "intends"; "anticipates"; "plans";
"expects"; "estimates"; or similar statements are forward-looking statements.
Forward looking statements include statements about the possible clinical
applications for caspase-1 in the field of cardiovascular diseases and
Biosite's ability to evaluate the diagnostic utility of the target. Risks
that should be considered include risks and uncertainties regarding the
discovery and product development process generally, risks associated with the
introduction of competitive products from companies with greater capital and
resources, uncertainties around the proprietary nature of the targets subject
to the collaboration, expansion or development of a direct sales effort in
domestic and international markets, and risks and expenses associated with
litigation, contract disputes, patent conflicts, product recalls,
manufacturing constraints, backlog, delays or inefficiencies, shipment
problems, seasonal customer demand, the timing of significant orders, changes
in reimbursement policies, regulatory changes, competitive pressures on
average selling prices, and the other risks detailed in Biosite's most recent
Annual Report on Form 10-K, as amended, and other SEC filings. Biosite
disclaims, any intent or obligation to update these forward-looking
statements. Copies of Biosite's public disclosure filings are available from
its investor relations department.
Biosite(R), Triage(R) and New Dimensions in Diagnosis(R) are registered
trademarks of Biosite Incorporated. The Company's logo is a trademark of
Biosite Incorporated.
SOURCE Biosite Incorporated
 back to top
Related links:
http://www.biosite.com
Company News On-Call:
http://www.prnewswire.com/comp/116737.html
CONTACT:
Nadine Padilla, VP, Corporate & Investor
Relations of Biosite Incorporated, +1-858-455-4808, ext. 3187,
npadilla@biosite.com
|
